Back to Search Start Over

Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.

Authors :
Musumeci F
Sanna M
Grossi G
Brullo C
Fallacara AL
Schenone S
Source :
Current medicinal chemistry [Curr Med Chem] 2017; Vol. 24 (19), pp. 2059-2085.
Publication Year :
2017

Abstract

The pyrrolo[2,3-d]pyrimidine nucleus is a deaza-isostere of adenine, the nitrogenous base of ATP, and is present in many ATP-competitive inhibitors of different kinases. In the last few years the number of articles and patents that have appeared involving this type of inhibitors has dramatically increased and some compounds have been approved for the treatment of inflammatory or myeloproliferative diseases. Other derivatives are currently being evaluated in clinical trials. This review deals with pyrrolo[2,3- d]pyrimidine derivatives active as kinase inhibitors that have been reported in the literature from 2011 to 2016, with a particular interest on the recently patented compounds. The molecules are classified depending on the inhibited kinase, focusing on their chemical structures.<br /> (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)

Details

Language :
English
ISSN :
1875-533X
Volume :
24
Issue :
19
Database :
MEDLINE
Journal :
Current medicinal chemistry
Publication Type :
Academic Journal
Accession number :
28266267
Full Text :
https://doi.org/10.2174/0929867324666170303162100